NASDAQ:BDRX Biodexa Pharmaceuticals Q4 2025 Earnings Results & Report $0.46 -0.06 (-12.13%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.46 0.00 (-0.04%) As of 10/9/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Biodexa Pharmaceuticals beat analyst earnings expectations in its Q4 2025 results, released March 27, 2026. The company reported EPS of $3.5250 versus the -$0.0066 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 27, 2026TimeBefore Market OpensConference Call8:00 AM ET Biodexa Pharmaceuticals EPS ResultsActual EPS$3.5250Consensus EPS -$0.0066Beat/MissBeat by +$3.5316One Year Ago EPSN/ABiodexa Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(20-F) Biodexa Pharmaceuticals Q4 2025 Earnings FAQ Did Biodexa Pharmaceuticals beat earnings estimates for Q4 2025? Biodexa Pharmaceuticals (NASDAQ:BDRX) reported earnings of $3.5250 per share for Q4 2025, beating the consensus estimate of -$0.0066. The report was announced on Friday, March 27, 2026. Biodexa Pharmaceuticals Earnings HeadlinesBiodexa Pharmaceuticals Stock Set to Reverse Split on Monday, October 26th (NASDAQ:BDRX)October 10 at 1:21 AM | americanbankingnews.comBDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 PatientsSeptember 22, 2026 | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 11 at 1:00 AM | Chaikin Analytics (Ad)Biodexa Enters Warrant Exercise Deal For $2 Mln As Phase 3 For ERapa Progresses; Stock Plunges 25%September 16, 2026 | rttnews.comBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsSeptember 15, 2026 | globenewswire.comCorning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market SessionSeptember 14, 2026 | benzinga.comSee More Biodexa Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biodexa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biodexa Pharmaceuticals and other key companies, straight to your email. Email Address About Biodexa PharmaceuticalsBiodexa Pharmaceuticals (NASDAQ:BDRX) plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods. Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma. The company has also developed drug-delivery technologies intended to improve the administration, absorption and targeting of therapeutics. Its technology portfolio has included Q-Sphera, a platform designed to produce long-acting injectable medicines, along with other delivery approaches for localized or sustained drug release. Biodexa is headquartered in the United Kingdom and has conducted development activities in the United States and other international markets. The company’s programs remain subject to clinical, regulatory and commercial development requirements.View Biodexa Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
